Association of Dialysis Adequacy, Physical and Emotional Symptoms with Erythropoietin-stimulating agent Responsiveness in Iraqi Patients Undergoing Hemodialysis
DOI:
https://doi.org/10.32947/ajps.v24i1.1038Keywords:
ESRD, Anemia, ESA, Kt/V, dialysis symptom indexAbstract
Background: Erythropoietin (EPO)-deficient anemia occurs in patients with chronic kidney disease (CKD). Erythropoietin-stimulating agents (ESAs) are the standard treatment for CKD anemia, but patient responses vary.
Hemodialysis patients are often anemic due to hypo erythropoiesis and their chronic inflammatory state. Inadequate dialysis is considered one of the factors that are linked to ESA hypo responsiveness. Dialysis patients may experience many symptoms that lower their quality of life. End stage renal disease (ESRD) symptoms are assessed using Dialysis Symptom Index (DSI).
Objective: The current study was designed to measure the association between physical, and emotional symptoms and ESA responsiveness. Also, to determine how dialysis adequacy affects response level.
Materials and Methods: The current study included 150 CKD anemic patients in a multicenter dialysis units. patients were examined for the response to Epoetin alfa (Eprex) after 12 weeks in this cross-sectional study. Clinical, demographic, and laboratory data were collected. The erythropoietin resistance index (ERI) evaluated the effect of erythropoietin dosage on hemoglobin levels. Dialysis adequacy (Kt/V) measured the efficacy of dialysis. The severity of symptoms was evaluated using the 30-question Dialysis Symptom Index (DSI).
Results: 150 patients in all were enrolled, with a mean age of 51.6 ± 14.9 for the male patients. There was a significant difference in kt/v among study groups, mainly between hypo response and resistance groups (P-value < 0.01). However, there was no statistically significant difference in the DSI mean (P = 0.4). kt/v was positively correlated with the duration of dialysis and parathyroid hormone (PTH) (R = 0.27, P-value < 0.001), (R = 0.19, P-value = 0.01). additionally, The DSI was strongly connected with the age of the patients (R = 0.18, P-value = 0.02).
Conclusion: One of the main causes of Eprex resistance in this study was insufficient dialysis. Patients who received longer hemodialysis sessions exhibited higher hemodialysis sufficiency. However, there was no significant association between DSI and degree of response across research groups, and older hemodialysis patients experienced higher dialysis-related symptoms.
References
- Vaidya SR, Aeddula NR. Chronic Renal Failure. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC.; 2023.
- Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019 Jan;62(1):3-16. DOI: https://doi.org/10.1007/s00125-018-4711-2
- Malekmakan L, Tadayon T, Roozbeh J, Sayadi M. End-stage Renal Disease in the Middle East: a Systematic Review and Meta-analysis. Iranian journal of kidney diseases. 2018;12:195-203.
- Kareem A, Al-Juboori K, Khudhur I, Hussain Faris S. Professor; Psychiatric Mental Health, 3 Lecture, Family and Community Health Nursing Department. 2020.
- Mohammed RB, Mohammed MM, Naeemah SJ. Clinical Evaluation of Niacin in Hemodialysis Patients with Hyperphosphatemia as Adjuvant to Calcium Carbonate. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2020;20(3):82-93. DOI: https://doi.org/10.32947/ajps.v20i3.764
- You AS, Kalantar SS, Norris KC, Peralta RA, Narasaki Y, Fischman R, et al. Dialysis symptom index burden and symptom clusters in a prospective cohort of dialysis patients. J Nephrol. 2022;35(5):1427-36. DOI: https://doi.org/10.1007/s40620-022-01313-0
- O'connor NR, Corcoran AM. End-stage renal disease: symptom management and advance care planning. American family physician. 2012;85(7):705-10.
- Long B, Koyfman A, Lee CM. Emergency medicine evaluation and management of the end stage renal disease patient. The American journal of emergency medicine.2017;35(12):1946-55. DOI: https://doi.org/10.1016/j.ajem.2017.09.002
- Leake AE, Yuo TH, Wu T, Fish L, Dillavou ED, Chaer RA, et al. Arteriovenous grafts are associated with earlier catheter removal and fewer catheter days in the United States Renal Data System population. Journal of Vascular Surgery. 2015;62(1):123-7. DOI: https://doi.org/10.1016/j.jvs.2015.02.018
- Alattiya TN, Mohammed MM, Jaleel NA, Jamil N, Al-Sabbag MS. Effect of oral L-carnitine supplementation on the mortality markers in hemodialysis patients. Int J Pharm Sci Rev Res. 2016;14:64-9.
- Somji SS, Ruggajo P, Moledina S. Adequacy of Hemodialysis and Its Associated Factors among Patients Undergoing Chronic Hemodialysis in Dar es Salaam, Tanzania. Int J Nephrol. 2020;2020:9863065. DOI: https://doi.org/10.1155/2020/9863065
- McMurray J, Parfrey P, Adamson JW, Aljama P, Berns JS, Bohlius J, et al. Kidney disease: Improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney International Supplements. 2012:279-335.
- Gaweda AE, Goldsmith LJ, Brier ME, Aronoff GR. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response. Clinical Journal of the American Society of Nephrology. 2010;5(4):576-81. DOI: https://doi.org/10.2215/CJN.04710709
- Manuti J, Alwan A, Ali M. Hyporesponsiviness to Erythropoietin Therapy in End Stage Renal Disease Patients on Regular Haemodialysis. Clinical Medicine Research. 2021;10:191. DOI: https://doi.org/10.11648/j.cmr.20211006.14
- Ryu S-R, Park SK, Jung JY, Kim YH, Oh YK, Yoo TH, et al. The prevalence and management of anemia in chronic kidney disease patients: result from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD). Journal of Korean medical science. 2017;32(2):249-56. DOI: https://doi.org/10.3346/jkms.2017.32.2.249
- Hazin MAA. Anemia in chronic kidney disease. Revista da Associação Médica Brasileira. 2020;66:s55-s8. DOI: https://doi.org/10.1590/1806-9282.66.s1.55
- Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23(10):1631-4. DOI: https://doi.org/10.1681/ASN.2011111078
- Alves MT, Vilaça SS, Carvalho MdG, Fernandes AP, Dusse LMSA, Gomes KB. Resistance of dialyzed patients to erythropoietin. Revista brasileira de hematologia e hemoterapia. 2015;37:190-7. DOI: https://doi.org/10.1016/j.bjhh.2015.02.001
- Macdougall IC, Meadowcroft AM, Blackorby A, Cizman B, Cobitz AR, Godoy S, et al. Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D). American Journal of Nephrology. 2023;54(1-2):1-13. DOI: https://doi.org/10.1159/000528696
- Yasin A, Omran N. Hyporesponsiveness to Erythropoietin-Stimulating Agents: Possible Solutions. Updates on Hemodialysis: IntechOpen; 2023. DOI: https://doi.org/10.5772/intechopen.109988
- López-Gómez JM, Portolés JM, Aljama P. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality: New strategies to prevent cardiovascular risk in chronic kidney disease. Kidney International. 2008;74:S75-S81. DOI: https://doi.org/10.1038/ki.2008.523
- Mallick S, Rafiroiu A, Kanthety R, Iqbal S, Malik R, Rahman M. Factors predicting erythropoietin resistance among maintenance hemodialysis patients. Blood purification. 2012;33(4):238-44. DOI: https://doi.org/10.1159/000335256
- El-Sheikh M, El-Ghazaly G. Assessment of hemodialysis adequacy in patients with chronic kidney disease in the hemodialysis unit at Tanta University Hospital in Egypt. Indian J Nephrol. 2016;26(6):398-404. DOI: https://doi.org/10.4103/0971-4065.168141
- Tang CY, Zhu CP, Wang RP, Ye XQ, Chen XF, Feng WN, et al. Effect of blood pump flow and arteriovenous fistula blood flow on the blood pressure and cardiac function in patients undergoing maintenance hemodialysis. Therapeutic Apheresis and Dialysis. 2019;23(6):556-61. DOI: https://doi.org/10.1111/1744-9987.12809
- Lambie SH, Taal MW, Fluck RJ, McIntyre CW. Analysis of factors associated with variability in haemodialysis adequacy. Nephrology Dialysis Transplantation. 2004;19(2):406-12. DOI: https://doi.org/10.1093/ndt/gfg570
- Fishbane S, Spinowitz B. Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018. American Journal of Kidney Diseases. 2018;71(3):42335. DOI: https://doi.org/10.1053/j.ajkd.2017.09.026
- Bermejo F, García-López S. A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases. World journal of gastroenterology: WJG. 2009;15(37):4638. DOI: https://doi.org/10.3748/wjg.15.4638
- Rezaiee O, Shahgholian N, Shahidi S. Assessment of hemodialysis adequacy and its relationship with individual and personal factors. Iranian journal of nursing and midwifery research. 2016;21(6):577. DOI: https://doi.org/10.4103/1735-9066.197673
- Wang X, Shi Q, Mo Y, Liu J, Yuan Y. Palliative care needs and symptom burden in younger and older patients with end-stage renal disease undergoing maintenance hemodialysis: A cross-sectional study. International Journal of Nursing Sciences. 2022;9(4):422-9. DOI: https://doi.org/10.1016/j.ijnss.2022.09.015
- Abedi-Samakoosh M, Ahangarkani F, Aghaie N, Gholami F, Shirzad M, Naseripour Z. The relationship between the adequacy of hemodialysis and laboratory parameters. Chronic Diseases Journal. 2017:19-27.
- Mohammed RB, Mohammed MM. Potential role of Niacin as Adjuvant to Sevelamer on Serum levels of Inorganic phosphorus, Calcium and Calcium-phosphorus product in Hemodialysis patients with Hyperphosphatemia. Age (year). 2022;48:12.77. DOI: https://doi.org/10.52711/0974-360X.2022.00358
- Molony DA, Stephens BW. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations. Advances in chronic kidney disease. 2011;18(2):120-31. https://doi.org/10.1053/j.ackd.2011.02.004 DOI: https://doi.org/10.1053/j.ackd.2011.02.004
- Eidman KE, Wetmore JB. Managing hyperparathyroidism in hemodialysis: role of etelcalcetide. Int J Nephrol Renovasc Dis. 2018;11:69-80. DOI: https://doi.org/10.2147/IJNRD.S128252
- KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1-59. DOI: https://doi.org/10.1016/j.kisu.2017.04.001
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Salar Ahmed, Mohammed Mahmood, Arif Sami
This work is licensed under a Creative Commons Attribution 4.0 International License.
